HACOR Score Calculator- Free HFNC Failure Prediction Tool

HACOR Score Calculator: Predicting High-Flow Nasal Cannula Failure in Acute Respiratory Failure

When a patient in respiratory distress is placed on high-flow nasal cannula (HFNC) oxygen therapy, clinicians face a critical question: is this working, or will the patient need intubation? The HACOR score was developed to answer exactly that question. By combining five bedside parameters – heart rate, acidosis, consciousness, oxygenation, and respiratory rate – into a single numerical score, the HACOR scale provides a structured, evidence-based method for identifying patients at high risk of HFNC failure early enough to intervene.

Understanding when HFNC is succeeding and when it is buying time before inevitable intubation is one of the most consequential judgments in critical care medicine. Delayed intubation in patients who ultimately fail HFNC is associated with higher mortality, longer ICU stays, and worse outcomes. The HACOR score, validated in multicenter prospective studies, offers clinicians a reliable numerical anchor for this decision.

What Is the HACOR Score?

The HACOR score was first described by Dr. Jun-Hua Chen and colleagues in a 2017 study published in Critical Care. The score was designed specifically to predict failure of high-flow nasal cannula therapy in patients with acute hypoxemic respiratory failure (AHRF). HFNC failure is defined as the need to escalate to non-invasive ventilation (NIV) or invasive mechanical ventilation during or after an HFNC trial.

The score evaluates five clinical parameters that are readily available at the bedside without additional laboratory testing beyond an arterial blood gas (ABG):

• H – Heart Rate: Elevated heart rate reflects sympathetic activation and increased work of breathing.
• A – Acidosis: Arterial pH below 7.35 indicates metabolic or respiratory compensation failure.
• C – Consciousness: Altered mental status using the Glasgow Coma Scale (GCS) reflects the severity of hypoxemia and cerebral impact.
• O – Oxygenation: The ratio of arterial oxygen partial pressure to fraction of inspired oxygen (PaO2/FiO2 ratio), a standard measure of oxygenation efficiency.
• R – Respiratory Rate: Tachypnea persisting despite HFNC support indicates ongoing respiratory distress.

Each parameter is assigned a score based on severity thresholds, and the total ranges from 0 to 25. A score above 5 at 1-2 hours after HFNC initiation has been shown in validation studies to predict HFNC failure with strong discriminative ability.

HACOR Score Component Breakdown

Heart Rate (HR) – 0 to 2 Points

The heart rate component reflects adrenergic stress and the physiologic burden imposed by respiratory failure. Patients with normal or mildly elevated heart rates score 0 to 1, while those with heart rates above 120 beats per minute score 2. Severe tachycardia in this context indicates that the patient’s respiratory muscles and cardiovascular system are under significant strain, a sign that HFNC may not be providing adequate unloading.

• HR 100 or below: 0 points
• HR 101 to 120: 1 point
• HR above 120: 2 points

Acidosis (Arterial pH) – 0 to 4 Points

Arterial pH is one of the most heavily weighted components in the HACOR score. Acidosis – whether respiratory (rising PaCO2), metabolic, or mixed – reflects inadequate gas exchange and systemic compensation failure. A pH below 7.25 carries the maximum score of 4 points, consistent with severe acidemia that almost always requires escalation of ventilatory support. Even mild acidosis (pH 7.35 to 7.40) contributes 1 point, recognizing that any deviation from normal is clinically relevant in this population.

• pH 7.50 or above: 0 points
• pH 7.40 to 7.49: 0 points
• pH 7.35 to 7.39: 1 point
• pH 7.25 to 7.34: 2 points
• pH below 7.25: 4 points

Consciousness (Glasgow Coma Scale) – 0 to 10 Points

The consciousness component, scored using the Glasgow Coma Scale, is the most heavily weighted HACOR parameter with a maximum of 10 points. This reflects the critical importance of mental status in HFNC candidacy. HFNC relies on the patient’s ability to maintain airway patency, follow instructions, and tolerate the therapy. Patients with significant obtundation (GCS 11 to 14) or severe impairment (GCS 10 or below) are at substantially higher risk of failure, both because their underlying condition is more severe and because they may not be able to cooperate with the therapy.

• GCS 15: 0 points
• GCS 13 to 14: 2 points
• GCS 11 to 12: 5 points
• GCS 10 or below: 10 points

Oxygenation (PaO2/FiO2 Ratio) – 0 to 6 Points

The P/F ratio (PaO2/FiO2) is the standard measure of oxygenation in acute respiratory failure and forms the basis of ARDS classification. In the HACOR score, it contributes up to 6 points. A P/F ratio above 200 mmHg scores 0 – these patients have adequate oxygenation despite respiratory failure. Severe hypoxemia (P/F below 100) scores the maximum 6 points. The P/F ratio must be measured from an arterial blood gas, not estimated from pulse oximetry alone, for accurate HACOR calculation.

• P/F above 300: 0 points
• P/F 201 to 300: 1 point
• P/F 101 to 200: 3 points
• P/F 100 or below: 6 points

Respiratory Rate (RR) – 0 to 3 Points

Respiratory rate is a fundamental vital sign that directly reflects the work of breathing. Despite HFNC’s ability to reduce inspiratory effort, patients who remain tachypneic (above 25 to 30 breaths per minute) on therapy are demonstrating inadequate respiratory compensation. A respiratory rate above 30 breaths per minute scores 3 points, while normal rates (24 or below) score 0.

• RR 24 or below: 0 points
• RR 25 to 30: 1 point
• RR above 30: 3 points

Clinical Interpretation of HACOR Scores

The HACOR score is most meaningful when measured at 1 to 2 hours after HFNC initiation, once the patient has had adequate time to respond to therapy. Early assessment (less than 30 minutes) may not reflect the patient’s true trajectory.

The original validation study by Chen et al. (2017) found that a HACOR score above 5 at 1-2 hours had an area under the receiver operating characteristic (AUROC) curve of 0.85 for predicting HFNC failure, indicating strong discriminative ability. In that cohort, patients with HACOR scores above 5 who were intubated had significantly better outcomes than those in whom intubation was delayed.

Subsequent validation studies have confirmed the score’s utility across different populations, including COVID-19 pneumonia patients, though the specific thresholds may require calibration for different populations and clinical settings.

High-Flow Nasal Cannula: How It Works

High-flow nasal cannula delivers heated, humidified oxygen at flow rates up to 60 liters per minute with adjustable FiO2 from 21% to 100%. Unlike conventional oxygen via nasal prongs or face mask, HFNC provides several physiologic benefits that make it a preferred initial respiratory support option for many patients with acute hypoxemic respiratory failure:

• Positive airway pressure effect: High flows generate low levels of positive end-expiratory pressure (approximately 1-3 cmH2O), reducing atelectasis and improving functional residual capacity.
• Washout of anatomical dead space: Continuous high-flow oxygen flushes CO2 from the nasopharynx and upper airway, reducing the dead space fraction and improving efficiency of each breath.
• Precise FiO2 delivery: Unlike conventional oxygen masks, HFNC delivers a predictable FiO2, making the P/F ratio calculation more reliable.
• Reduced inspiratory effort: High-flow delivery reduces the work of breathing by matching or exceeding the patient’s peak inspiratory flow demand.
• Patient comfort: Heated humidification reduces mucosal dryness and allows the patient to speak, eat, and expectorate.

Despite these advantages, HFNC is not suitable for all forms of respiratory failure. It is most effective for pure hypoxemic failure (Type 1) and less effective for hypercapnic failure (Type 2), where non-invasive positive pressure ventilation (NIPPV/BiPAP) is typically preferred. The HACOR score was developed specifically in the context of acute hypoxemic respiratory failure patients trialed on HFNC.

Why Predicting HFNC Failure Matters: The Danger of Delayed Intubation

One of the most important lessons from critical care research over the past decade is that late intubation in patients who fail non-invasive respiratory support carries significant mortality risk. When a patient is failing HFNC but intubation is delayed – sometimes because clinicians are hoping for improvement, or because the decision is difficult – the patient may arrive at intubation in a more compromised physiologic state: more hypoxic, more acidotic, more exhausted, and with a higher aspiration risk.

The 2015 FLORALI trial and subsequent studies demonstrated that in patients with moderate to severe AHRF (P/F below 200), HFNC reduced intubation rates and 90-day mortality compared to conventional oxygen. However, this benefit was only observed when intubation decisions were made in a timely manner in patients who failed. The HACOR score was designed to provide a structured, objective framework to support that decision – moving away from purely gestalt-based assessments toward a reproducible clinical tool.

HACOR Score in COVID-19 and Acute Respiratory Distress Syndrome

The COVID-19 pandemic dramatically increased the clinical use of HFNC globally, making tools like the HACOR score particularly relevant. Several studies evaluated the HACOR score in COVID-19-associated AHRF, generally finding that it retained predictive validity, though the distribution of scores and failure rates differed from pre-pandemic cohorts.

In COVID-19 ARDS, a unique phenotype of hypoxemia – often with preserved respiratory mechanics early in the disease – meant that some patients tolerated HFNC despite quite low P/F ratios. The respiratory rate and consciousness components of HACOR remained strong predictors of failure even in this atypical population. Several investigators suggested that repeated HACOR scoring (at 1, 6, and 12 hours) improved prediction in COVID-19 patients compared to a single early score.

For patients with classic ARDS from any cause, the HACOR score performs similarly to the original validation cohort. In moderate to severe ARDS (P/F below 150 to 200), the threshold for proceeding to intubation rather than prolonged HFNC trials is generally lower, and the HACOR score should be interpreted in this context.

Comparison with Other HFNC Failure Prediction Tools

Several other tools exist for predicting HFNC failure, each with different clinical advantages and limitations.

ROX Index: The Respiratory Rate – OXygenation (ROX) index, defined as SpO2/FiO2/respiratory rate, is a simpler bedside score that does not require an arterial blood gas. It was validated primarily in pneumonia patients. An ROX index above 4.88 at 2, 6, or 12 hours is associated with HFNC success. The ROX index is easier to calculate continuously but lacks the consciousness and acidosis components that give HACOR additional discriminative power.

SOFA Score: The Sequential Organ Failure Assessment score is not specific to HFNC but provides a broader assessment of organ dysfunction. High SOFA scores at HFNC initiation are associated with failure, but the SOFA score was not designed for this purpose and lacks the respiratory specificity of HACOR.

SpO2/FiO2 Ratio: The SF ratio can be used when arterial blood gas is unavailable, but it is less accurate than the P/F ratio and does not capture the full clinical picture captured by HACOR.

The HACOR score’s advantage lies in its integration of multiple physiologic domains into a single validated number, with the GCS component providing unique insight into neurological tolerance of hypoxemia that simpler oxygenation-focused indices miss.

Limitations of the HACOR Score

No clinical prediction tool is perfect, and the HACOR score has important limitations that clinicians should recognize:

• Requires arterial blood gas: The pH and PaO2 components require ABG sampling, which may not be immediately available in all settings.
• Not validated for all populations: The original validation was in adults with AHRF. Applicability to pediatric populations, immunocompromised patients, or those with chronic hypoxemia (e.g., severe COPD with baseline hypoxemia) requires caution.
• FiO2 estimation with HFNC: While HFNC FiO2 is more reliable than conventional oxygen masks, actual delivered FiO2 can vary with patient effort and mouth breathing. This affects P/F ratio accuracy.
• Single time-point limitation: A single HACOR score captures a snapshot. Trending the score over the first few hours provides more information than any single measurement.
• Clinical context matters: A patient with a HACOR score of 6 who is clearly improving on HFNC differs from one with the same score who is deteriorating. The score supplements, but does not replace, clinical judgment.
• Not a scoring system for non-HFNC patients: The HACOR score was not designed for patients on standard oxygen, NIV, or mechanical ventilation. Using it in these contexts is outside its validated application.

Implementing HACOR Score Monitoring in Clinical Practice

For clinical teams wishing to implement structured HACOR scoring, the following protocol reflects evidence-based practice:

Timing of Assessments: Obtain a baseline HACOR score at HFNC initiation, then repeat at 1 to 2 hours. For high-risk patients (score above 5) or those with ARDS, reassess every 2 to 4 hours. For stable patients (score 5 or below), reassess at 6 and 12 hours, then every 12 hours thereafter if remaining on HFNC.

Action Thresholds: A HACOR score above 5 at 1-2 hours should trigger a senior clinician review and preparation for potential escalation. The team should ensure the patient, family, and care team are aligned on escalation plans. A rising HACOR score (even if below 5) warrants increased monitoring frequency.

Documentation: Serial HACOR scores should be documented in the medical record to allow trending and retrospective audit of HFNC management decisions.

Validation Studies and Evidence Base

The original HACOR score was derived and validated in a prospective multicenter study by Chen et al. (2017, Critical Care) involving 449 patients across multiple Chinese ICUs. The study found that a HACOR score above 5 at 1-2 hours after HFNC initiation had an AUROC of 0.85, sensitivity of 72%, and specificity of 81% for predicting HFNC failure.

A key finding of the original study was that early intubation in patients with HACOR above 5 was associated with significantly lower hospital mortality compared to delayed intubation in the same high-risk group (37.9% vs 70.3% mortality). This dramatic mortality difference provides a compelling argument for using the score to prompt earlier intubation decisions in high-risk patients.

Subsequent external validation studies have confirmed the score’s utility in diverse populations including European ICU cohorts, COVID-19 patients, and immunocompromised patients, though specific AUROC values and optimal cutoffs have varied somewhat by population.

Global Application and Population Considerations

The HACOR score was initially developed and validated in a Chinese population but has since been applied and validated across diverse global populations. Its physiologic parameters – heart rate, pH, GCS, P/F ratio, and respiratory rate – are universally measured and interpreted similarly across healthcare systems.

Studies in European, North American, and Asian populations have found consistent predictive validity, though baseline patient characteristics and intubation thresholds vary between healthcare systems. In settings where HFNC is used more aggressively before intubation (as has been common in resource-limited settings during the COVID-19 pandemic), the score’s positive predictive value for failure at the greater than 5 threshold may be higher, reflecting a more severely ill patient population on HFNC.

The score has been studied in specific ethnic and clinical subpopulations, including patients with haematological malignancies (where intubation carries very high mortality risk), with general agreement that the HACOR score provides useful risk stratification even in these high-stakes populations. Some investigators have proposed modified thresholds for immunocompromised patients, though these have not been universally adopted.

HACOR Score and Shared Decision-Making

One often-overlooked application of the HACOR score is in facilitating structured conversations about escalation of care. When a patient or family is faced with the decision about whether to proceed with intubation, a validated numerical score can help anchor the discussion. Rather than relying purely on abstract descriptions of “serious” or “very serious” respiratory failure, clinicians can explain that the patient’s HACOR score indicates a specific level of risk, supporting more informed shared decision-making.

This is particularly relevant when patients have expressed preferences about the extent of life-sustaining treatment, or when the clinical team is uncertain whether aggressive intervention is aligned with the patient’s values and goals.

Frequently Asked Questions

Conclusion

The HACOR score represents a significant advance in the structured assessment of patients receiving high-flow nasal cannula therapy for acute hypoxemic respiratory failure. By integrating heart rate, acidosis, consciousness, oxygenation, and respiratory rate into a single validated score, it provides clinicians with an objective, reproducible framework for identifying patients at high risk of HFNC failure – and for timing escalation decisions that can meaningfully affect patient outcomes.

The evidence is clear: patients with HACOR scores above 5 at 1 to 2 hours who receive timely escalation to mechanical ventilation have substantially better outcomes than those in whom intubation is delayed. At the same time, the score must be used as a component of clinical reasoning rather than a standalone decision-making algorithm. Patient trajectory, underlying diagnosis, goals of care, and clinical context all shape how HACOR scores translate into action.

As HFNC use continues to expand globally – in ICUs, emergency departments, and increasingly in general ward settings – structured monitoring tools like the HACOR score become ever more essential. This calculator provides a convenient, accurate tool for bedside HACOR assessment, supporting timely and evidence-informed care for critically ill patients with respiratory failure. All clinical decisions based on this score should be made in consultation with qualified critical care physicians and healthcare professionals with expertise in respiratory failure management.